Skip to main content
x

Recent articles

An ozekibart reminder about liver toxicity

Inhibrx reveals three deaths in phase 1, but all predate screening protocols.

BeOne joins the Kat6 pack

BG-75202 features among several projects starting first-in-human trials.

Pfizer moves into the VEGF bispecific fast lane

There will soon be three PD-(L)1 x VEGF projects in pivotal lung and colorectal cancer trials.

Amgen's $1.9bn looks buried

The Fortitude-102 trial, testing a bemarituzumab/Opdivo/chemo triplet, has failed.

One of Adcetris’s twin sons strikes out

Pfizer cans PF-08046045, but keeps PF-08046044 for now.

Venture capitalists buy into TROP2

Blackstone follows Abingworth, but why?